Skip to main content
SpringerLink
Log in
Book cover

Lipid-mediated Protein Signaling pp 105–139Cite as

Role of Phosphatidylinositol 3,4,5-Trisphosphate in Cell Signaling

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 991))

Abstract

Many lipids present in cellular membranes are phosphorylated as part of signaling cascades and participate in the recruitment, localization, and activation of downstream protein effectors. Phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3) is one of the most important second messengers and is capable of interacting with a variety of proteins through specific PtdIns(3,4,5)P3 binding domains. Localization and activation of these effector proteins controls a myriad of cellular functions including cell survival, proliferation, cytoskeletal rearrangement, and gene expression. Aberrations in the production and metabolism of PtdIns(3,4,5)P3 have been implicated in many human diseases including cancer, diabetes, inflammation, and heart disease. This chapter provides an overview of the role of PtdIns(3,4,5)P3 in cellular regulation and the implications of PtdIns(3,4,5)P3 dysregulation in human diseases. Additionally, recent attempts at targeting PtdIns(3,4,5)P3 signaling via small molecule inhibitors are summarized.

Robert D. Riehle and Sinziana Cornea contributed equally to this work.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Hokin MR, Hokin LE (1953) Enzyme secretion and the incoroporation of P32 into phospolipides of pancreas slices. J Biol Chem 203(2):967–977

    PubMed  CAS  Google Scholar 

  2. Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM (1985) Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315(6016):239–242

    PubMed  CAS  Google Scholar 

  3. Traynor-Kaplan AE, Harris AL, Thompson BL, Taylor P, Sklar LA (1988) An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature 334(6180):353–356

    PubMed  CAS  Google Scholar 

  4. Whitman M, Downes CP, Keeler M, Keller T, Cantley L (1988) Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332(6165):644–646

    PubMed  CAS  Google Scholar 

  5. Rameh LE, Cantley LC (1999) The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274(13):8347–8350

    PubMed  CAS  Google Scholar 

  6. Rusten TE, Stenmark H (2006) Analyzing phosphoinositides and their interacting proteins. Nat Method 3(4):251–258

    CAS  Google Scholar 

  7. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD (2001) Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70(1):535

    PubMed  CAS  Google Scholar 

  8. Hawkins PT, Jackson TR, Stephens LR (1992) Platelet-derived growth factor stimulates synthesis of Ptdlns(3,4,5)P3 by activating a Ptdlns(4,5)P2 3-OH kinase. Nature 358(6382):157–159

    PubMed  CAS  Google Scholar 

  9. Kavran JM, Klein DE, Lee A, Falasca M, Isakoff SJ, Skolnik EY, Lemmon MA (1998) Specificity and promiscuity in phosphoinositide binding by pleckstrin homology domains. J Biol Chem 273(46):30497–30508

    PubMed  CAS  Google Scholar 

  10. Kwiatkowska K (2010) One lipid, multiple functions: how various pools of PI(4,5)P3 are created in the plasma membrane. Cell Mol Life Sci 67(23):3927–3946

    PubMed  CAS  Google Scholar 

  11. Lemmon MA, Ferguson KM, O’Brien R, Sigler PB, Schlessinger J (1995) Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain. Proc Natl Acad Sci U S A 92(23):10472–10476

    PubMed  CAS  Google Scholar 

  12. Martin TFJ (2001) PI(4,5)P2 regulation of surface membrane traffic. Curr Opin Cell Biol 13(4):493–499

    PubMed  CAS  Google Scholar 

  13. Castellano E, Santos E (2011) Functional specificity of Ras isoforms. Genes Cancer 2(3):216–231

    PubMed  CAS  Google Scholar 

  14. Erneux C, Edimo WE, Deneubourg L, Pirson I (2011) SHIP2 multiple functions: a balance between a negative control of PtdIns(3,4,5)P(3) level, a positive control of PtdIns(3,4)P(2) production, and intrinsic docking properties. J Cell Biochem 112(9):2203–2209

    PubMed  CAS  Google Scholar 

  15. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JRE, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3K, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19(6):715–727

    PubMed  CAS  Google Scholar 

  16. Koyasu S (2003) The role of PI3K in immune cells. Nat Immunol 4(4):313–319

    PubMed  CAS  Google Scholar 

  17. Rosen SAJ, Gaffney PRJ, Spiess B, Gould IR (2012) Understanding the relative affinity and specificity of the pleckstrin homology domain of protein kinase B for inositol phosphates. Phys Chem Chem Phys 14(2):929–936

    PubMed  CAS  Google Scholar 

  18. Sun H, Lesche R, Li D-M, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, Wu H (1999) PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 96(11):6199–6204

    PubMed  CAS  Google Scholar 

  19. Kashiwada M, Lu P, Rothman P (2007) PIP3 pathway in regulatory T cells and autoimmunity. Immunol Res 39(1):194–224

    PubMed  CAS  Google Scholar 

  20. Wisniewski D, Strife A, Swendeman S, Erdjument-Bromage H, Geromanos S, Kavanaugh WM, Tempst P, Clarkson B (1999) A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93(8):2707–2720

    PubMed  CAS  Google Scholar 

  21. Blero D, Payrastre B, Schurmans S, Erneux C (2007) Phosphoinositide phosphatases in a network of signalling reactions. Pflugers Arch 455(1):31–44

    PubMed  CAS  Google Scholar 

  22. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM (2011) INPP4B: the new kid on the PI3K block. Oncotarget 2(4):321–328

    PubMed  Google Scholar 

  23. He J, Haney RM, Vora M, Verkhusha VV, Stahelin RV, Kutateladze TG (2008) Molecular mechanism of membrane targeting by the GRP1 PH domain. J Lipid Res 49(8):1807–1815

    PubMed  CAS  Google Scholar 

  24. Thomas CC, Deak M, Alessi DR, van Aalten DMF (2002) High-resolution structure of the pleckstrin homology domain of protein kinase B/Akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 12(14):1256–1262

    PubMed  CAS  Google Scholar 

  25. Bayascas JR, Wullschleger S, Sakamoto K, García-Martínez JM, Clacher C, Komander D, van Aalten DMF, Boini KM, Lang F, Lipina C, Logie L, Sutherland C, Chudek JA, van Diepen JA, Voshol PJ, Lucocq JM, Alessi DR (2008) Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol 28(10):3258–3272

    PubMed  CAS  Google Scholar 

  26. Vr C, Alcor D, Laguerre M, Park J, Vojnovic B, Hemmings BA, Downward J, Parker PJ, Larijani B (2007) Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol 5(4):e95

    Google Scholar 

  27. Milburn CC, Deak M, Kelly SM, Price NC, Alessi DR, Van Aalten DMF (2003) Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J 375(Pt 3):531–538

    PubMed  CAS  Google Scholar 

  28. Currie RA, Walker KS, Gray A, Deak M, Casamayor A, Downes CP, Cohen P, Alessi DR, Lucocq J (1999) Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 337(Pt 3):575–583

    PubMed  CAS  Google Scholar 

  29. McManus EJ, Collins BJ, Ashby PR, Prescott AR, Murray-Tait V, Armit LJ, Arthur JSC, Alessi DR (2004) The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J 23(10):2071–2082

    PubMed  CAS  Google Scholar 

  30. Gao X, Harris TK (2006) Role of the PH domain in regulating in vitro autophosphorylation events required for reconstitution of PDK1 catalytic activity. Bioorg Chem 34(4):200–223

    PubMed  Google Scholar 

  31. DiNitto JP, Delprato A, Gabe Lee M-T, Cronin TC, Huang S, Guilherme A, Czech MP, Lambright DG (2007) Structural basis and mechanism of autoregulation in 3-phosphoinositide-dependent Grp1 family Arf GTPase exchange factors. Mol Cell 28(4):569–583

    PubMed  CAS  Google Scholar 

  32. van der Vos KE, Coffer PJ (2011) The extending network of FOXO transcriptional target genes. Antioxid Redox Signal 14(4):579–592

    PubMed  Google Scholar 

  33. Lew DJ, Dulic V, Reed SI (1991) Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 66(6):1197–1206

    PubMed  CAS  Google Scholar 

  34. Furukawa-Hibi Y, Kobayashi Y, Chen C, Motoyama N (2005) FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 7(5–6):752–760

    PubMed  CAS  Google Scholar 

  35. Marone R, Cmiljanovic V, Giese B, Wymann MP (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta -Proteins Proteomics 1784(1):159–185

    CAS  Google Scholar 

  36. Zhou BP, Liao Y, Xia W, Spohn B, Lee M-H, Hung M-C (2001) Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3(3):245–252

    PubMed  CAS  Google Scholar 

  37. Worster DT, Schmelzle T, Solimini NL, Lightcap ES, Millard B, Mills GB, Brugge JS, Albeck JG (2012) Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci Signal 5(214):ra19

    PubMed  Google Scholar 

  38. Manning BD, Cantley LC (2003) United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 31(Pt 3):573–578

    PubMed  CAS  Google Scholar 

  39. Yang Q, Guan KL (2007) Expanding mTOR signaling. Cell Res 17(8):666–681

    PubMed  CAS  Google Scholar 

  40. Fenton TR, Gout IT (2011) Functions and regulation of the 70 kDa ribosomal S6 kinases. Int J Biochem Cell Biol 43(1):47–59

    PubMed  CAS  Google Scholar 

  41. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21(3):297–308

    PubMed  CAS  Google Scholar 

  42. Ward PS, Thompson CB (2012) Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol 4(7)

    Google Scholar 

  43. Johnson DE (1998) Regulation of survival pathways by IL-3 and induction of apoptosis following IL-3 withdrawal. Front Biosci 3:d313–d324

    PubMed  CAS  Google Scholar 

  44. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278(5338):687–689

    PubMed  Google Scholar 

  45. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke TF (1997) Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci U S A 94(21):11345–11350

    PubMed  CAS  Google Scholar 

  46. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN (1997) Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A 94(8):3627–3632

    PubMed  CAS  Google Scholar 

  47. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, Greenberg ME (2000) 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 6(1):41–51

    PubMed  CAS  Google Scholar 

  48. Lizcano JM, Morrice N, Cohen P (2000) Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J 349(Pt 2):547–557

    PubMed  CAS  Google Scholar 

  49. Tan Y, Demeter MR, Ruan H, Comb MJ (2000) BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem 275(33):25865–25869

    PubMed  CAS  Google Scholar 

  50. Harada H, Becknell B, Wilm M, Mann M, Huang LJ, Taylor SS, Scott JD, Korsmeyer SJ (1999) Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 3(4):413–422

    PubMed  CAS  Google Scholar 

  51. Tan Y, Ruan H, Demeter MR, Comb MJ (1999) p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem 274(49):34859–34867

    PubMed  CAS  Google Scholar 

  52. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286(5443):1358–1362

    PubMed  CAS  Google Scholar 

  53. Tzivion G, Dobson M, Ramakrishnan G (2011) FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813(11):1938–1945

    PubMed  CAS  Google Scholar 

  54. Zhang X, Tang N, Hadden TJ, Rishi AK (2011) Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 1813(11):1978–1986

    PubMed  CAS  Google Scholar 

  55. Hay N (2011) Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta 1813(11):1965–1970

    PubMed  CAS  Google Scholar 

  56. Forde JE, Dale TC (2007) Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 64(15):1930–1944

    PubMed  CAS  Google Scholar 

  57. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401(6748):82–85

    PubMed  CAS  Google Scholar 

  58. Romashkova JA, Makarov SS (1999) NF-kappa B is a target of AKT in anti-apoptotic PDGF signalling. Nature 401(6748):86–90

    PubMed  CAS  Google Scholar 

  59. Genevier HC, Hinshelwood S, Gaspar HB, Rigley KP, Brown D, Saeland S, Rousset F, Levinsky RJ, Callard RE, Kinnon C et al (1994) Expression of Bruton’s tyrosine kinase protein within the B cell lineage. Eur J Immunol 24(12):3100–3105

    CAS  Google Scholar 

  60. Buggy JJ, Elias L (2012) Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 31(2):119–132

    CAS  Google Scholar 

  61. Anderson JS, Teutsch M, Dong Z, Wortis HH (1996) An essential role for Bruton’s [corrected] tyrosine kinase in the regulation of B-cell apoptosis. Proc Natl Acad Sci U S A 93(20):10966–10971

    PubMed  CAS  Google Scholar 

  62. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K (2004) Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 117(6):787–800

    PubMed  CAS  Google Scholar 

  63. Niiro H, Clark EA (2002) Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2(12):945–956

    PubMed  CAS  Google Scholar 

  64. Khare A, Viswanathan B, Gund R, Jain N, Ravindran B, George A, Rath S, Bal V (2011) Role of Bruton’s tyrosine kinase in macrophage apoptosis. Apoptosis 16(4):334–346

    PubMed  CAS  Google Scholar 

  65. Raimondi C, Falasca M (2011) Targeting PDK1 in cancer. Curr Med Chem 18(18):2763–2769

    PubMed  CAS  Google Scholar 

  66. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA (2009) AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1):21–32

    PubMed  CAS  Google Scholar 

  67. Fernando HS, Kynaston HG, Jiang WG (2009) WASP and WAVE proteins: vital intrinsic regulators of cell motility and their role in cancer. Int J Mol Med 23(2):141–148

    PubMed  CAS  Google Scholar 

  68. Wong W (2012) Focus issue: a cell’s sense of direction. Sci Signal 5(213):eg3

    PubMed  Google Scholar 

  69. Oikawa T, Yamaguchi H, Itoh T, Kato M, Ijuin T, Yamazaki D, Suetsugu S, Takenawa T (2004) PtdIns(3,4,5)P3 binding is necessary for WAVE2-induced formation of lamellipodia. Nat Cell Biol 6(5):420–426

    PubMed  CAS  Google Scholar 

  70. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR (2003) Cell migration: integrating signals from front to back. Science 302(5651):1704–1709

    PubMed  CAS  Google Scholar 

  71. Takahashi K, Suzuki K (2010) WAVE2 targeting to phosphatidylinositol 3,4,5-triphosphate mediated by insulin receptor substrate p53 through a complex with WAVE2. Cell Signal 22(11):1708–1716

    PubMed  CAS  Google Scholar 

  72. Morimura S, Suzuki K, Takahashi K (2011) Nonmuscle myosin IIA is required for lamellipodia formation through binding to WAVE2 and phosphatidylinositol 3,4,5-triphosphate. Biochem Biophys Res Commun 404(3):834–840

    PubMed  CAS  Google Scholar 

  73. Chen C-L, Wang Y, Sesaki H, Iijima M (2012) Myosin I links PIP3 signaling to remodeling of the actin cytoskeleton in chemotaxis. Sci Signal 5(209):ra10

    PubMed  Google Scholar 

  74. Chin YR, Toker A (2011) Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adh Migr 5(3):211–214

    PubMed  Google Scholar 

  75. Primo L, di Blasio L, Roca C, Droetto S, Piva R, Schaffhausen B, Bussolino F (2007) Essential role of PDK1 in regulating endothelial cell migration. J Cell Biol 176(7):1035–1047

    PubMed  CAS  Google Scholar 

  76. Dong LQ, Landa LR, Wick MJ, Zhu L, Mukai H, Ono Y, Liu F (2000) Phosphorylation of protein kinase N by phosphoinositide-dependent protein kinase-1 mediates insulin signals to the actin cytoskeleton. Proc Natl Acad Sci U S A 97(10):5089–5094

    PubMed  CAS  Google Scholar 

  77. Pinner S, Sahai E (2008) PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 10(2):127–137

    PubMed  CAS  Google Scholar 

  78. Schneider E, Keppler R, Prawitt D, Steinwender C, Roos FC, Thuroff JW, Lausch E, Brenner W (2011) Migration of renal tumor cells depends on dephosphorylation of Shc by PTEN. Int J Oncol 38(3):823–831

    PubMed  CAS  Google Scholar 

  79. Ananthanarayanan B, Ni Q, Zhang J (2005) Signal propagation from membrane messengers to nuclear effectors revealed by reporters of phosphoinositide dynamics and Akt activity. Proc Natl Acad Sci U S A 102(42):15081–15086

    PubMed  CAS  Google Scholar 

  80. Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A, Lucocq J, Downes CP (2006) Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci 119(24):5160–5168

    PubMed  CAS  Google Scholar 

  81. Lian Z, Di Cristofano A (2005) Class reunion: PTEN joins the nuclear crew. Oncogene 24(50):7394–7400

    PubMed  CAS  Google Scholar 

  82. Ahn JY, Liu X, Cheng D, Peng J, Chan PK, Wade PA, Ye K (2005) Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD. Mol Cell 18(4):435–445

    PubMed  CAS  Google Scholar 

  83. Kwon IS, Lee KH, Choi JW, Ahn JY (2010) PI(3,4,5)P3 regulates the interaction between Akt and B23 in the nucleus. BMB Rep 43(2):127–132

    PubMed  CAS  Google Scholar 

  84. Kumar A, Fernandez-Capetillo O, Carrera AC (2010) Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc Natl Acad Sci U S A 107(16):7491–7496

    PubMed  CAS  Google Scholar 

  85. Bertagnolo V, Brugnoli F, Marchisio M, Celeghini C, Carini C, Capitani S (2004) Association of PI 3-K with tyrosine phosphorylated Vav is essential for its activity in neutrophil-like maturation of myeloid cells. Cell Signal 16(4):423–433

    PubMed  CAS  Google Scholar 

  86. Aoki K, Nakamura T, Fujikawa K, Matsuda M (2005) Local phosphatidylinositol 3,4,5-trisphosphate accumulation recruits Vav2 and Vav3 to activate Rac1/Cdc42 and initiate neurite outgrowth in nerve growth factor-stimulated PC12 cells. Mol Biol Cell 16(5):2207–2217

    PubMed  CAS  Google Scholar 

  87. Vedham V, Phee H, Coggeshall KM (2005) Vav activation and function as a rac guanine nucleotide exchange factor in macrophage colony-stimulating factor-induced macrophage chemotaxis. Mol Cell Biol 25(10):4211–4220

    PubMed  CAS  Google Scholar 

  88. Jiang H, Guo W, Liang X, Rao Y (2005) Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3β and its upstream regulators. Cell 120(1):123–135

    PubMed  CAS  Google Scholar 

  89. Dotti CG, Sullivan CA, Banker GA (1988) The establishment of polarity by hippocampal neurons in culture. J Neurosci 8(4):1454–1468

    PubMed  CAS  Google Scholar 

  90. Yan D, Guo L, Wang Y (2006) Requirement of dendritic Akt degradation by the ubiquitin-proteasome system for neuronal polarity. J Cell Biol 174(3):415–424

    PubMed  CAS  Google Scholar 

  91. Horiguchi K, Hanada T, Fukui Y, Chishti AH (2006) Transport of PIP3 by GAKIN, a kinesin-3 family protein, regulates neuronal cell polarity. J Cell Biol 174(3):425–436

    PubMed  CAS  Google Scholar 

  92. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510

    PubMed  CAS  Google Scholar 

  93. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606–619

    PubMed  CAS  Google Scholar 

  94. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

    PubMed  CAS  Google Scholar 

  95. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501

    PubMed  CAS  Google Scholar 

  96. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562

    PubMed  CAS  Google Scholar 

  97. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261–1274

    PubMed  CAS  Google Scholar 

  98. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2):231–241

    PubMed  CAS  Google Scholar 

  99. Bader AG, Kang S, Zhao L, Vogt PK (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5(12):921–929

    PubMed  CAS  Google Scholar 

  100. Tzivion G, Dobson M, Ramakrishnan G (2011) FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta (BBA) – Mol Cell Res 1813(11):1938–1945

    CAS  Google Scholar 

  101. Plas DR, Thompson CB (2005) Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24(50):7435–7442

    PubMed  CAS  Google Scholar 

  102. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7(1):11–20

    PubMed  CAS  Google Scholar 

  103. Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2(4):339–345

    PubMed  CAS  Google Scholar 

  104. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K, Tsichlis PN (2009) MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2(92):ra62

    PubMed  Google Scholar 

  105. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117–1134

    PubMed  CAS  Google Scholar 

  106. Arteaga CL (2006) EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell 9(6):421–423

    PubMed  CAS  Google Scholar 

  107. Narita Y, Nagane M, Mishima K, Huang H-JS, Furnari FB, Cavenee WK (2002) Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62(22):6764–6769

    PubMed  CAS  Google Scholar 

  108. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4):320–368

    PubMed  CAS  Google Scholar 

  109. Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol Mech 3(1):557–586

    CAS  Google Scholar 

  110. Eggermont AMM, Robert C (2012) Melanoma in 2011: a new paradigm tumor for drug development. Nat Rev Clin Oncol 9(2):74–76

    PubMed  CAS  Google Scholar 

  111. Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3(10):1221–1224

    PubMed  CAS  Google Scholar 

  112. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068

    CAS  Google Scholar 

  113. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, DeLong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561–573

    PubMed  CAS  Google Scholar 

  114. Zhao L, Vogt PK (2010) Hot-spot mutations in p110α of phosphatidylinositol 3-kinase (PI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9(3):596–600

    PubMed  CAS  Google Scholar 

  115. Carson JD, Van Aller G, Lehr R, Sinnamon RH, Kirkpatrick RB, Auger KR, Dhanak D, Copeland RA, Gontarek RR, Tummino PJ, Luo L (2008) Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 409(2):519–524

    PubMed  CAS  Google Scholar 

  116. Chaussade C, Cho K, Mawson C, Rewcastle GW, Shepherd PR (2009) Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem Biophys Res Commun 381(4):577–581

    PubMed  CAS  Google Scholar 

  117. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, Asaoka Y, Matsumura M, Kawabe T, Omata M (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65(11):4562–4567

    PubMed  CAS  Google Scholar 

  118. Kang S, Bader AG, Vogt PK (2005) Phosphatid­ylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102(3):802–807

    PubMed  CAS  Google Scholar 

  119. Sugita H, Dan S, Kong D, Tomida A, Yamori T (2008) A new evaluation method for quantifying PI3K activity by HTRF assay. Biochem Biophys Res Commun 377(3):941–945

    PubMed  CAS  Google Scholar 

  120. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM (2005) The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 102(51):18443–18448

    PubMed  CAS  Google Scholar 

  121. Denley A, Gymnopoulos M, Kang S, Mitchell C, Vogt PK (2009) Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res 7(7):1132–1138

    PubMed  CAS  Google Scholar 

  122. Vadas O, Burke JE, Zhang X, Berndt A, Williams RL (2011) Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal 4(195):re2

    PubMed  Google Scholar 

  123. Miled N, Yan Y, Hon W-C, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317(5835):239–242

    PubMed  CAS  Google Scholar 

  124. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943–1947

    PubMed  CAS  Google Scholar 

  125. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15(4):356–362

    PubMed  CAS  Google Scholar 

  126. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19(4):348–355

    PubMed  Google Scholar 

  127. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 96(4):1563–1568

    PubMed  CAS  Google Scholar 

  128. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, Barrantes IB, Ho A, Wakeham A, ltie A, Khoo W, Fukumoto M, Mak TW (1998) High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol:CB 8(21):1169–1178

    CAS  Google Scholar 

  129. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP (1999) Impaired Fas response and autoimmunity in Pten+/− mice. Science 285(5436):2122–2125

    PubMed  Google Scholar 

  130. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP (2001) Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27(2):222–224

    PubMed  Google Scholar 

  131. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J, Pandolfi PP (2010) Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42(5):454–458

    PubMed  CAS  Google Scholar 

  132. Salmena L, Carracedo A, Pandolfi PP (2008) Tenets of PTEN tumor suppression. Cell 133(3):403–414

    PubMed  CAS  Google Scholar 

  133. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13(5):283–296

    PubMed  CAS  Google Scholar 

  134. Berger AH, Knudson AG, Pandolfi PP (2011) A continuum model for tumour suppression. Nature 476(7359):163–169

    PubMed  CAS  Google Scholar 

  135. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128(1):157–170

    PubMed  CAS  Google Scholar 

  136. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP (2011) Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144(2):187–199

    PubMed  CAS  Google Scholar 

  137. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, Yu L, Fernandez SA, Pecot T, Rosol TJ, Cory S, Hallett M, Park M, Piper MG, Marsh CB, Yee LD, Jimenez RE, Nuovo G, Lawler SE, Chiocca EA, Leone G, Ostrowski MC (2012) Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol 14(2):159–167

    CAS  Google Scholar 

  138. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong J-L, Naidu S, Wei G, Sharma SM, Stephens JA, Fernandez SA, Gurcan MN, Weinstein MB, Barsky SH, Yee L, Rosol TJ, Stromberg PC, Robinson ML, Pepin F, Hallett M, Park M, Ostrowski MC, Leone G (2009) Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461(7267):1084–1091

    PubMed  CAS  Google Scholar 

  139. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, McCubrey JA, Travali S, Libra M (2012) Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance. Int J Oncol 40(3):639–644

    PubMed  CAS  Google Scholar 

  140. Xu J, Zhou J-Y, Wei W-Z, Wu GS (2010) Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5(4):e10226

    PubMed  Google Scholar 

  141. Okkenhaug K, Vanhaesebroeck B (2003) PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 3(4):317–330

    PubMed  CAS  Google Scholar 

  142. Blunt MD, Ward SG (2012) Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia. Curr Opin Pharmacol 12(4):444–451

    PubMed  CAS  Google Scholar 

  143. Van Haastert PJM, Devreotes PN (2004) Chemotaxis: signalling the way forward. Nat Rev Mol Cell Biol 5(8):626–634

    PubMed  Google Scholar 

  144. Hawkins PT, Stephens LR, Suire S, Wilson M (2010) PI3K signaling in neutrophils. Curr Top Microbiol Immunol 346:183–202

    PubMed  CAS  Google Scholar 

  145. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP (2000) Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287(5455):1049–1053

    PubMed  CAS  Google Scholar 

  146. Williams CMM, Galli SJ (2000) The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol 105(5):847–859

    PubMed  CAS  Google Scholar 

  147. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I, Joza N, Mak TW, Ohashi PS, Suzuki A, Penninger JM (2000) Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 287(5455):1040–1046

    PubMed  CAS  Google Scholar 

  148. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE (2003) Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement. J Immunol 170(5):2647–2654

    PubMed  CAS  Google Scholar 

  149. Ferrandi C, Ardissone V, Ferro P, Ruckle T, Zaratin P, Ammannati E, Hauben E, Rommel C, Cirillo R (2007) Phosphoinositide 3-kinase γ inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment. J Pharmacol Exp Ther 322(3):923–930

    PubMed  CAS  Google Scholar 

  150. Vemula S, Shi J, Hanneman P, Wei L, Kapur R (2010) ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 115(9):1785–1796

    PubMed  CAS  Google Scholar 

  151. Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K, Vanhaesebroeck B, Turner M, Webb L, Wymann MP, Hirsch E, Ruckle T, Camps M, Rommel C, Jackson SP, Chilvers ER, Stephens LR, Hawkins PT (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106(4):1432–1440

    PubMed  CAS  Google Scholar 

  152. Perisic O, Wilson MI, Karathanassis D, Jn B, Pacold ME, Ellson CD, Hawkins PT, Stephens L, Williams RL (2004) The role of phosphoinositides and phosphorylation in regulation of NADPH oxidase. Adv Enzyme Regul 44(1):279–298

    PubMed  CAS  Google Scholar 

  153. Fung-Leung W-P (2011) Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function. Cell Signal 23(4):603–608

    PubMed  CAS  Google Scholar 

  154. Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17(11):1410–1422

    PubMed  CAS  Google Scholar 

  155. Kaplan MJ (2011) Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 7(12):691–699

    PubMed  CAS  Google Scholar 

  156. Wedemeyer J, Tsai M, Galli SJ (2000) Roles of mast cells and basophils in innate and acquired immunity. Curr Opin Immunol 12(6):624–631

    PubMed  CAS  Google Scholar 

  157. Rommel C, Camps M, Ji H (2007) PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7(3):191–201

    PubMed  CAS  Google Scholar 

  158. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddings J, Peskett E, Fox R, Bruce I, Walker C, Sawyer C, Okkenhaug K, Finan P, Vanhaesebroeck B (2004) Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 431(7011):1007–1011

    PubMed  CAS  Google Scholar 

  159. Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, Hirsch E, Wymann MP (2002) Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function. Immunity 16(3):441–451

    PubMed  CAS  Google Scholar 

  160. Furumoto Y, Brooks S, Olivera A, Takagi Y, Miyagishi M, Taira K, Casellas R, Beaven MA, Gilfillan AM, Rivera J (2006) Cutting edge: lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival. J Immunol 176(9):5167–5171

    PubMed  CAS  Google Scholar 

  161. Furumoto Y, Charles N, Olivera A, Leung WH, Dillahunt S, Sargent JL, Tinsley K, Odom S, Scott E, Wilson TM, Ghoreschi K, Kneilling M, Chen M, Lee DM, Bolland S, Rivera J (2011) PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability. Blood 118(20):5466–5475

    PubMed  CAS  Google Scholar 

  162. Shenker BJ, Boesze-Battaglia K, Zekavat A, Walker L, Besack D, Ali H (2010) Inhibition of mast cell degranulation by a chimeric toxin containing a novel phosphatidylinositol-3,4,5-triphosphate phosphatase. Mol Immunol 48(1‚Äì3):203–210

    PubMed  CAS  Google Scholar 

  163. Shenker BJ, Ali H, Boesze-Battaglia K (2011) PIP3 regulation as promising targeted therapy of mast-cell-mediated diseases. Curr Pharm Des 17(34):3815–3822

    PubMed  CAS  Google Scholar 

  164. Fruman DA, Bismuth G (2009) Fine tuning the immune response with PI3K. Immunol Rev 228(1):253–272

    PubMed  CAS  Google Scholar 

  165. Okkenhaug K, Fruman DA (2010) PI3Ks in lymphocyte signaling and development. Curr Top Microbiol Immunol 346:57–85

    PubMed  CAS  Google Scholar 

  166. Fayard E, Moncayo G, Hemmings BA, Hollander GA (2010) Phosphatidylinositol 3-kinase signaling in thymocytes: the need for stringent control. Sci Signal 3(135):re5

    PubMed  Google Scholar 

  167. Swat W, Montgrain V, Doggett TA, Douangpanya J, Puri K, Vermi W, Diacovo TG (2006) Essential role of PI3Kδ and PI3Kγ in thymocyte survival. Blood 107(6):2415–2422

    PubMed  CAS  Google Scholar 

  168. Webb LMC, Vigorito E, Wymann MP, Hirsch E, Turner M (2005) Cutting edge: T cell development requires the combined activities of the p110γ and p110δ catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 175(5):2783–2787

    PubMed  CAS  Google Scholar 

  169. Okkenhaug K, Patton DT, Bilancio A, Garcon F, Rowan WC, Vanhaesebroeck B (2006) The p110δ isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol 177(8):5122–5128

    PubMed  CAS  Google Scholar 

  170. Nombela-Arrieta C, Lacalle RA, Montoya MC, Kunisaki Y, Megias D, Marques M, Carrera AC, Manes S, Fukui Y, Martinez-A C, Stein JV (2004) Differential requirements for DOCK2 and phosphoinositide-3-kinase γ during T and B lymphocyte homing. Immunity 21(3):429–441

    PubMed  CAS  Google Scholar 

  171. Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG (2004) Cutting edge: differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in lymphocyte chemotaxis and homing. J Immunol 173(4):2236–2240

    PubMed  CAS  Google Scholar 

  172. Werner M, Hobeika E, Jumaa H (2010) Role of PI3K in the generation and survival of B cells. Immunol Rev 237(1):55–71

    PubMed  CAS  Google Scholar 

  173. Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA (2006) Sjogren’s syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proc Natl Acad Sci U S A 103(45):16882–16887

    PubMed  CAS  Google Scholar 

  174. Ohashi PS (2002) T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat Rev Immunol 2(6):427–438

    PubMed  CAS  Google Scholar 

  175. Okkenhaug K, Bilancio A, Gr F, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, Smith AJH, Vanhaesebroeck B (2002) Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297(5583):1031–1034

    PubMed  CAS  Google Scholar 

  176. So L, Fruman DA (2012) PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 442(3):465–481

    PubMed  CAS  Google Scholar 

  177. Oudit GY, Sun H, Kerfant B-G, Crackower MA, Penninger JM, Backx PH (2004) The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37(2):449–471

    PubMed  CAS  Google Scholar 

  178. Oudit GY, Penninger JM (2009) Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 82(2):250–260

    PubMed  CAS  Google Scholar 

  179. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng H-YM, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM (2002) Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110(6):737–749

    PubMed  CAS  Google Scholar 

  180. Northcott CA, Poy MN, Najjar SM, Watts SW (2002) Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ Res 91(4):360–369

    PubMed  CAS  Google Scholar 

  181. Wymann MP, Zvelebil M, Laffargue M (2003) Phosphoinositide 3-kinase signalling – which way to target? Trends Pharmacol Sci 24(7):366–376

    PubMed  CAS  Google Scholar 

  182. Chavakis E, Carmona G, Urbich C, Göttig S, Henschler R, Penninger JM, Zeiher AM, Chavakis T, Dimmeler S (2008) Phosphatidylinositol-3-kinase γ is integral to homing functions of progenitor cells. Circ Res 102(8):942–949

    PubMed  CAS  Google Scholar 

  183. Cieslik K, Abrams CS, Wu KK (2001) Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase γ/Janus kinase 2/MEK-1-dependent pathway. J Biol Chem 276(2):1211–1219

    PubMed  CAS  Google Scholar 

  184. Oudit GY, Crackower MA, Eriksson U, Sarao R, Kozieradzki I, Sasaki T, Irie-Sasaki J, Gidrewicz D, Rybin VO, Wada T, Steinberg SF, Backx PH, Penninger JM (2003) Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108(17):2147–2152

    PubMed  CAS  Google Scholar 

  185. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S (2003) Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 100(21):12355–12360

    PubMed  CAS  Google Scholar 

  186. Huang J, Kontos CD (2002) PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 277(13):10760–10766

    PubMed  CAS  Google Scholar 

  187. Schwartzbauer G, Robbins J (2001) The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem 276(38):35786–35793

    PubMed  CAS  Google Scholar 

  188. Chaanine AH, Hajjar RJ (2011) AKT signalling in the failing heart. Eur J Heart Fail 13(8):825–829

    PubMed  CAS  Google Scholar 

  189. Sugden PH, Fuller SJ, Weiss SC, Clerk A (2008) Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol 153(S1):S137–S153

    PubMed  CAS  Google Scholar 

  190. DeBosch B, Sambandam N, Weinheimer C, Courtois M, Muslin AJ (2006) Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem 281(43):32841–32851

    PubMed  CAS  Google Scholar 

  191. DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Courtois M, Muslin AJ (2006) Akt1 is required for physiological cardiac growth. Circulation 113(17):2097–2104

    PubMed  CAS  Google Scholar 

  192. Hers I, Vincent EE, Tavare JM (2011) Akt signalling in health and disease. Cell Signal 23(10):1515–1527

    PubMed  CAS  Google Scholar 

  193. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S (2002) Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22(8):2799–2809

    PubMed  CAS  Google Scholar 

  194. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MVG, Napoli C, Sadoshima J, Croce CM, Ross J (2002) Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A 99(19):12333–12338

    PubMed  CAS  Google Scholar 

  195. Cook SA, Matsui T, Li L, Rosenzweig A (2002) Transcriptional effects of chronic Akt activation in the heart. J Biol Chem 277(25):22528–22533

    PubMed  CAS  Google Scholar 

  196. Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2(10):769–776

    PubMed  CAS  Google Scholar 

  197. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN (2002) Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 99(2):907–912

    PubMed  CAS  Google Scholar 

  198. McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA, Mollica JP, Zhang L, Zhang Y, Shioi T, Buerger A, Izumo S, Jay PY, Jennings GL (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 104(2):612–617

    PubMed  CAS  Google Scholar 

  199. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, Penninger JM, Backx PH, Oudit GY, Tsushima RG (2008) Phosphatidylinositol 3-kinase γ is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res 103(6):643–653

    PubMed  CAS  Google Scholar 

  200. Murphy E, Tong H, Steenbergen C (2003) Preconditioning: is the Akt-ion in the PI3K pathway? J Mol Cell Cardiol 35(9):1021–1025

    PubMed  CAS  Google Scholar 

  201. Yellon DM, Downey JM (2003) Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83(4):1113–1151

    PubMed  CAS  Google Scholar 

  202. Gross ER, Hsu AK, Gross GJ (2004) Opioid-induced cardioprotection occurs via glycogen synthase kinase β inhibition during reperfusion in intact rat hearts. Circ Res 94(7):960–966

    PubMed  CAS  Google Scholar 

  203. Cai Z, Semenza GL (2005) PTEN activity is modulated during ischemia and reperfusion. Circ Res 97(12):1351–1359

    PubMed  CAS  Google Scholar 

  204. Siddall H, Warrell C, Yellon D, Mocanu M (2008) Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. Basic Res Cardiol 103(6):560–568

    PubMed  CAS  Google Scholar 

  205. Poornima IG, Parikh P, Shannon RP (2006) Diabetic cardiomyopathy. Circ Res 98(5):596–605

    PubMed  CAS  Google Scholar 

  206. Kim K-H, Oudit GY, Backx PH (2008) Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 324(1):160–169

    PubMed  CAS  Google Scholar 

  207. Carnevale D, Lembo G (2012) PI3Kγ in hypertension: a novel therapeutic target controlling vascular myogenic tone and target organ damage. Cardiovasc Res 95(4):403–408

    PubMed  CAS  Google Scholar 

  208. McMullen JR, Jay PY (2007) PI3K(p110α) inhibitors as anti-cancer agents: minding the heart. Cell Cycle 6(8):910–913

    PubMed  CAS  Google Scholar 

  209. Foukas LC, Withers DJ (2011) Phosphoinositide signalling pathways in metabolic regulation. In: Rommel C, Vanhaesebroeck B, Vogt PK (eds) Phosphoinositide 3-kinase in health and disease, vol 346, Current topics in microbiology and immunology. Springer, Berlin/Heidelberg, pp 115–141

    Google Scholar 

  210. Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414(6865):799–806

    PubMed  CAS  Google Scholar 

  211. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7(2):85–96

    PubMed  CAS  Google Scholar 

  212. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, Sancho S, Smith AJH, Withers DJ, Vanhaesebroeck B (2006) Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441(7091):366–370

    PubMed  CAS  Google Scholar 

  213. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125(4):733–747

    PubMed  CAS  Google Scholar 

  214. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, Dastru W, Martin EL, Silengo L, Altruda F, Turco E, Lanzetti L, Musiani P, Ruckle T, Rommel C, Backer JM, Forni G, Wymann MP, Hirsch E (2008) Phosphoinositide 3-kinase p110β activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 1(36):ra3

    PubMed  Google Scholar 

  215. Shulman GI (2004) Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology 19(4):183–190

    PubMed  CAS  Google Scholar 

  216. Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC (2005) Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol 25(5):1596–1607

    PubMed  CAS  Google Scholar 

  217. Kurlawalla-Martinez C, Stiles B, Wang Y, Devaskar SU, Kahn BB, Wu H (2005) Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol 25(6):2498–2510

    PubMed  CAS  Google Scholar 

  218. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim Y-J, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu H (2004) Live-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc Natl Acad Sci U S A 101(7):2082–2087

    PubMed  CAS  Google Scholar 

  219. Suwa A, Kurama T, Shimokawa T (2010) SHIP2 and its involvement in various diseases. Expert Opin Ther Targets 14(7):727–737

    PubMed  CAS  Google Scholar 

  220. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD (2001) Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 17(1):615–675

    PubMed  CAS  Google Scholar 

  221. Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR (2003) Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem 278(48):48453–48466

    PubMed  CAS  Google Scholar 

  222. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC (2005) The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 170(3):455–464

    PubMed  CAS  Google Scholar 

  223. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM (2005) Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54(8):2351–2359

    PubMed  CAS  Google Scholar 

  224. Kirwan JP, Varastehpour A, Jing M, Presley L, Shao J, Friedman JE, Catalano PM (2004) Reversal of insulin resistance postpartum is linked to enhanced skeletal muscle insulin signaling. J Clin Endocrinol Metab 89(9):4678–4684

    PubMed  CAS  Google Scholar 

  225. Luo J, Sobkiw CL, Hirshman MF, Logsdon MN, Li TQ, Goodyear LJ, Cantley LC (2006) Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab 3(5):355–366

    PubMed  CAS  Google Scholar 

  226. Taniguchi CM, Kondo T, Sajan M, Luo J, Bronson R, Asano T, Farese R, Cantley LC, Kahn CR (2006) Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCλ/ζ. Cell Metab 3(5):343–353

    PubMed  CAS  Google Scholar 

  227. Meshkani R, Adeli K (2009) Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 42(13‚Äì14):1331–1346

    PubMed  CAS  Google Scholar 

  228. Popa C, Netea MG, van Riel PLCM, van der Meer JWM, Stalenhoef AFH (2007) The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48(4):751–762

    PubMed  CAS  Google Scholar 

  229. Um SH, D’Alessio D, Thomas G (2006) Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 3(6):393–402

    PubMed  CAS  Google Scholar 

  230. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431(7005):200–205

    PubMed  CAS  Google Scholar 

  231. Thong FSL, Dugani CB, Klip A (2005) Turning signals on and off: GLUT4 traffic in the insulin-signaling highway. Physiology 20(4):271–284

    PubMed  CAS  Google Scholar 

  232. Barthel A, Schmoll D, Unterman TG (2005) FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab 16(4):183–189

    PubMed  CAS  Google Scholar 

  233. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). Science 292(5522):1728–1731

    PubMed  CAS  Google Scholar 

  234. Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, Kudlow JE, Michell RH, Olefsky JM, Field SJ, Evans RM (2008) Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 451(7181):964–969

    PubMed  CAS  Google Scholar 

  235. Hanover JA, Krause MW, Love DC (2010) The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine. Biochim Biophys Acta – Gen Subs 1800(2):80–95

    CAS  Google Scholar 

  236. Ande SR, Mishra S (2009) Prohibitin interacts with phosphatidylinositol 3,4,5-triphosphate (PIP3) and modulates insulin signaling. Biochem Biophys Res Commun 390(3):1023–1028

    PubMed  CAS  Google Scholar 

  237. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12(3):159–169

    PubMed  CAS  Google Scholar 

  238. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):15–31

    PubMed  CAS  Google Scholar 

  239. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627–644

    PubMed  CAS  Google Scholar 

  240. Baggiolini M, Dewald B, Schnyder J, Ruch W, Cooper PH, Payne TG (1987) Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. Exp Cell Res 169(2):408–418

    PubMed  CAS  Google Scholar 

  241. Arcaro A (1993) Wortmannin is a potent phosphatidylinostitol 3-kinase inhibitor: the role of phosphatidylinositol 3, 4, 5-trisphosphate in neutrophil responses. Biochem J 296:297–301

    PubMed  CAS  Google Scholar 

  242. Cleary J, Shapiro G (2010) Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep 12(2):87–94

    PubMed  CAS  Google Scholar 

  243. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G (2004) Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 3(7):763–772

    PubMed  CAS  Google Scholar 

  244. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269(7):5241–5248

    PubMed  CAS  Google Scholar 

  245. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68(1):206–215

    PubMed  CAS  Google Scholar 

  246. Rommel C (2010) Taking PI3Kδ and PI3Kγ one step ahead: dual active PI3Kdelta/gamma inhibitors for the treatment of immune-mediated inflammatory diseases. Curr Top Microbiol Immunol 346:279–299

    PubMed  CAS  Google Scholar 

  247. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O’Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA (2011) The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603–3612

    PubMed  CAS  Google Scholar 

  248. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA (2011) CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2):591–594

    PubMed  CAS  Google Scholar 

  249. Flinn IW, Schreeder MT, Coutre SE, Leonard J, Wagner-Johnston ND, De Vos S, Boccia RV, Holes L, Peterman S, Miller LL, Yu AS (2011) A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. ASCO Meet Abstr 29(15 suppl):3064

    Google Scholar 

  250. Ruckle T, Schwarz MK, Rommel C (2006) PI3Kγ inhibition: towards an ‘aspirin of the 21st century’? Nat Rev Drug Discov 5(11):903–918

    PubMed  Google Scholar 

  251. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C (2005) Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11(9):936–943

    PubMed  CAS  Google Scholar 

  252. Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA (2012) Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 17(1):69–95

    PubMed  Google Scholar 

  253. Berndt N, Yang H, Trinczek B, Betzi S, Zhang Z, Wu B, Lawrence NJ, Pellecchia M, Schonbrunn E, Cheng JQ, Sebti SM (2010) The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ 17(11):1795–1804

    PubMed  CAS  Google Scholar 

  254. Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J (1997) D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33(3):442–446

    PubMed  CAS  Google Scholar 

  255. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan B-S, Kotani H (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956–1967

    PubMed  CAS  Google Scholar 

  256. Burris HA, Siu LL, Infante JR, Wheler JJ, Kurkjian C, Opalinska J, Smith DA, Antal JM, Gauvin JL, Gonzalez T, Adams LM, Bedard P, Gerecitano JF, Kurzrock R, Moore KN, Morris SR, Aghajanian C (2011) Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. ASCO Meet Abstr 29(15 suppl):3003

    Google Scholar 

  257. Kurzrock R, Patnaik A, Rosenstein L, Fu S, Papadopoulos KP, Smith DA, Falchook GS, Chambers G, Gauvin JL, Naing A, Smith LS, Gonzalez T, Tsimberidou AM, Mays TA, Cox DS, Hong DS, DeMarini DJ, Le NT, Morris SR, Tolcher AW (2011) Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). ASCO Meet Abstr 29(15 suppl):3085

    Google Scholar 

  258. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, Kahana JA, Geske RS, Kleymenova EV, Choudhry AE, Lai Z, Leber JD, Minthorn EA, Strum SL, Wood ER, Huang PS, Copeland RA, Kumar R (2008) Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68(7):2366–2374

    PubMed  CAS  Google Scholar 

  259. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909–918

    PubMed  CAS  Google Scholar 

  260. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671–688

    PubMed  CAS  Google Scholar 

  261. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7(2):e38

    PubMed  Google Scholar 

  262. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284(12):8023–8032

    PubMed  CAS  Google Scholar 

  263. Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, Gray NS (2010) Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem 53(19):7146–7155

    PubMed  CAS  Google Scholar 

  264. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS (2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem 54(5):1473–1480

    PubMed  CAS  Google Scholar 

  265. McNamara CR, Degterev A (2011) Small – molecule inhibitors of the PI3K signaling network. Future Med Chem 3(5):549

    PubMed  CAS  Google Scholar 

  266. Emerling BM, Akcakanat A (2011) Targeting PI3K/mTOR signaling in cancer. Cancer Res 71(24):7351–7359

    PubMed  CAS  Google Scholar 

  267. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5):341–349

    PubMed  CAS  Google Scholar 

  268. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven BA, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67(12):5840–5850

    PubMed  CAS  Google Scholar 

  269. Serra V, Markman B, Scaltriti M, Eichhorn PJA, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68(19):8022–8030

    PubMed  CAS  Google Scholar 

  270. Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chone P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7(7):1851–1863

    PubMed  CAS  Google Scholar 

  271. Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl W, Baselga J (2010) First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients with advanced solid tumors. ASCO Meet Abstr 28(15 suppl):3005

    Google Scholar 

  272. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, Anak N, Hackl W, Baselga J (2012) Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 23(9):2399–2408

    PubMed  CAS  Google Scholar 

  273. Chang K-Y, Tsai S-Y, Wu C-M, Yen C-J, Chuang B-F, Chang J-Y (2011) Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res 17(22):7116–7126

    PubMed  CAS  Google Scholar 

  274. Robak T, Robak E (2012) Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs 21(7):921–947

    PubMed  CAS  Google Scholar 

  275. Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, Robinson WH, Buggy JJ (2011) The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 13(4):R115

    PubMed  CAS  Google Scholar 

  276. Ferguson KM, Kavran JM, Sankaran VG, Fournier E, Isakoff SJ, Skolnik EY, Lemmon MA (2000) Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains. Mol Cell 6(2):373–384

    PubMed  CAS  Google Scholar 

  277. Berrie C, Falasca M (2000) Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention. FASEB J 14(15):2618–2622

    PubMed  CAS  Google Scholar 

  278. Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S, Potter BVL, Broggini M, Maffucci T (2010) A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer 102(1):104–114

    PubMed  CAS  Google Scholar 

  279. Falasca M, Selvaggi F, Buus R, Sulpizio S, Edling CE (2011) Targeting phosphoinositide 3-kinase pathways in pancreatic cancer – from molecular signalling to clinical trials. Anti Cancer Agents Med Chem 11(5):455–463

    CAS  Google Scholar 

  280. Miao B, Skidan I, Yang J, Lugovskoy A, Reibarkh M, Long K, Brazell T, Durugkar KA, Maki J, Ramana CV, Schaffhausen B, Wagner G, Torchilin V, Yuan J, Degterev A (2010) Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci U S A 107(46):20126–20131

    PubMed  CAS  Google Scholar 

  281. Miao B, Skidan I, Yang J, You Z, Fu X, Famulok M, Schaffhausen B, Torchilin V, Yuan J, Degterev A (2011) Inhibition of cell migration by PITENINs: the role of ARF6. Oncogene 31(39):4317–4332

    PubMed  Google Scholar 

  282. Riehle RD, Cornea S, Degterev A, Torchilin VMicellar formulations of pro-apoptotic DM-PIT-1 analogs and TRAIL in vitro and in vivo. Drug Deliv 20(2):78–85

    Google Scholar 

  283. Kim SH, Juhnn YS, Song YS (2007) Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci 1095(1):82–89

    PubMed  CAS  Google Scholar 

  284. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z (2003) HER2/PI-3 K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22(21):3205–3212

    PubMed  CAS  Google Scholar 

  285. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395–402

    PubMed  CAS  Google Scholar 

  286. Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung M-C, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117–127

    PubMed  CAS  Google Scholar 

  287. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling Y-H, Byun D-S, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Soler RP, Mariadason JM (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68(6):1953–1961

    PubMed  CAS  Google Scholar 

  288. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11(4):909–920

    PubMed  CAS  Google Scholar 

  289. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM (2011) Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 226(11):2762–2781

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA, 02115, USA

    Robert D. Riehle

  2. Department of Biochemistry, Tufts University School of Medicine, Boston, MA, 02111, USA

    Sinziana Cornea & Alexei Degterev

Authors
  1. Robert D. Riehle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sinziana Cornea
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexei Degterev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexei Degterev .

Editor information

Editors and Affiliations

  1. , Biological Sciences, Virginia Tech, Kraft Drive 1981, Blacksburg, 24061, Virginia, USA

    Daniel G.S. Capelluto

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Riehle, R.D., Cornea, S., Degterev, A. (2013). Role of Phosphatidylinositol 3,4,5-Trisphosphate in Cell Signaling. In: Capelluto, D. (eds) Lipid-mediated Protein Signaling. Advances in Experimental Medicine and Biology, vol 991. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6331-9_7

Download citation

Publish with us

Policies and ethics

Search

Navigation